Index. Note: Page numbers of article titles are in boldface type.

Transcription

1 Note: Page numbers of article titles are in boldface type. A Adherence, to bismuth quadruple therapy, Adjuvant therapy, probiotics as, Age factors, in gastric cancer, , 616 AID protein, in gastric cancer, Allele-specific primer polymerase chain reaction, for antibiotic resistance, 584, 588 Amoxicillin in bismuth quadruple therapy, 552 in hybrid therapy, in triple therapy, , resistance to, 521, susceptibility to, 671 Antibiotics, resistance to. See Resistance, to antibiotics. APOBEC family, in gastric cancer, APRIL (A proliferation-inducing ligand), in MALT lymphoma, 650 Atrophic gastritis, , , B Bifidobacterium formulations, 530, Biopsy, , 614 Bismuth quadruple therapy, acceptability of, adherence to, amoxicillin in, bismuth forms in, 538 clinical trials of, 552, 554 components of, 540 doxycycline in, 547, 549 duration of, efficacy of, failure of, 547, for eradication, history of, 538 in sequential therapy, 552 meal considerations in, metronidazole resistance and, 542 outcome of, 547, packaging of, pathogenic considerations in, proton pump inhibitor dosage in, 556 recommendations for, Gastroenterol Clin N Am 44 (2015) /15/$ see front matter ª 2015 Elsevier Inc. All rights reserved. gastro.theclinics.com

2 692 Bismuth (continued ) side effects of, , C CagA protein antigens of, for vaccine development, in carcinogenesis, Cancer Genome Atlas, 626 Carcinogenesis, virulence factors in, Chemotherapy, for MALT lymphoma, 657 Chromosomal instability in gastric cancer, 632 tumors with, 626 Clarithromycin efficacy of, in hybrid therapy, in triple therapy, mechanism of action of, resistance to, 521, 525, susceptibility to, 671 Colorimetry, for antibiotic resistance, Concomitant therapy, 526 Culture, 510 Cytokines, in gastric cancer, D Deamination, in gastric cancer, DNA methylation, in gastric cancer, Doxycycline, in bismuth quadruple therapy, 547, 549 Dual priming oligonucleotide polymerase chain reaction, for antibiotic resistance, 583 Dyspepsia, endoscopy for, after Helicobacter pylori eradication for, E Electrocatalytic detection, of DNA sequences, for antibiotic resistance, 586 Endoscopy after Helicobacter pylori eradication, for dyspepsia, for gastric cancer, 598, for peptic ulcer, 598, need for, 598 for gastric cancer risk, 614 for Helicobacter pylori, in MALT lymphoma, Enzyme-linked immunosorbent assay, 513 Epigenetics, of gastric cancer, Epstein-Barr virus tumors, 626 European Commission, on probiotics,

3 693 European Gastrointestinal Lymphoma Study, 651 European Societies of Gastrointestinal Endoscopy and Pathology, 602 F Fluorescence in situ hybridization, for antibiotic resistance, Fluorescence resonance energy transfer, 579 Fluoroquinolone(s), resistance to, Fluoroquinolone quadruple therapy, Fluoroquinolone triple therapy, Food bismuth quadruple therapy treatment and, probiotics containing, 567 Free radicals, in gastric cancer, 632 Furazolidone, in triple therapy, G Gastric cancer. See also Mucosa-associated lymphoid tissue (MALT) lymphoma. characterization of, classification of, development from peptic ulcer, 600 early, endoscopy for, after Helicobacter pylori eradication, 598, epidemiology of, 678 epigenetics of, genetics of, inflammatory responses in, molecular pathogenesis of, natural history of, 616 prevention of, prognosis for, 641 risk of, assessment of, epidemiology of, 611 Helicobacter pylori in, hereditary, in eradicated patients, screening for, virulence factors in, Gastritis atrophic, , , in MALT lymphomas, 651 Gastroesophageal reflux disease, Helicobacter pylori eradication for, GastroPanel, Genetics, of gastric cancer, Genotype HelicoDR method, Giemsa stain, 509 Groupe d Etude des Lymphomes de l Adulte, 654 gyra quinolone resistance-determining region,

4 694 H Health insurance, for Helicobacter pylori eradication, Helicobacter pylori infections diagnosis of, epidemiology of, 520, eradication of, for gastroesophageal reflux disease, gastric cancer risk in, in high school students, in Japan, , outcomes of, gastric cancer in. See Gastric cancer. MALT lymphoma in. See Mucosa-associated lymphoid tissue (MALT) lymphoma. natural history of, 644 screening for, 668 test for, treatment of. See also Helicobacter pylori infections, eradication of. antimicrobial resistance in. See Resistance, to antibiotics. bismuth quadruple therapy for, difficulty with, endoscopy after, failure of, first-line regimens for, practical aspects of, probiotics for, 530, rescue therapy for, selection of, vaccine for, Hereditary risk, for gastric cancer, High school students, Helicobacter pylori eradication in, Histology, for gastric cancer risk, 614 for Helicobacter pylori infections, HOMER Study, 541 Hybrid (sequential-concomitant) therapy, Hypermethylation, in gastric cancer, Hypomethylation, in gastric cancer, I Immunotherapy, for MALT lymphoma, 657 In situ hybridization, Interleukins, in gastric cancer, International Scientific Association for Probiotics and Prebiotics, 566 Intestinal metaplasia, proton pump inhibitors and, Invader assay, for antibiotic resistance, J Japan, Helicobacter pylori eradication program in, , Japanese Society for Helicobacter Research, 643

5 695 L Laboratory tests, Lactobacillus clinical use of, 567 for Helicobacter pylori infections, formulations for, 530 in natural foods, 567 Lactoferrin formulations, 530, 568 Lauren classification, of gastric cancer, 626 Levofloxacin, in triple therapy, Lugano International Conference, on MALT lymphoma, Lymphoma, MALT. See Mucosa-associated lymphoid tissue (MALT) lymphoma. Lynch syndrome, M Maaastricht consensus, 510 Macrolides, resistance to, MALT lymphoma. See Mucosa-associated lymphoid tissue (MALT) lymphoma. Meals, bismuth quadruple therapy treatment and, Melting curve analysis, Mesenchymal tumors, 627 Metronidazole, 522. See also Bismuth quadruple therapy. resistance to, 521, , susceptibility to, 671 Microelectronic chip assay, for antibiotic resistance, 586 MicroRNAs, in gastric cancer, 633 Microsatellite instability, 626 Molecular tests, Mongolian gerbil model, for gastric cancer, Mucosa-associated lymphoid tissue (MALT) lymphoma, diagnosis of, differential diagnosis of, 651 endoscopy for, genetics of, 650 pathogenesis of, 650 staging of, 652 treatment of, Multiplex polymerase chain reaction, for antibiotic resistance, 588 N Nested polymerase chain reaction, for antibiotic resistance, Nitroimidazole efficacy of, in hybrid therapy, in triple therapy, , resistance to, Nuclear factor-kb, in gastric cancer,

6 696 O Omeprazole, 522, 540 Operative Link for Gastritis Assessment or Metaplasia, 602, 615 Oxidative stress, in gastric cancer, P Pantoprazole, 572 Paris staging system, on MALT lymphoma, Pepsinogens, in atrophic gastritis, Peptic ulcer causes of, 600 complicated, 601 endoscopy for, after Helicobacter pylori eradication for, 598, pathogenesis of, treatment of, Peptide nucleic acid fluorescence in situ hybridization, for antibiotic resistance, Peptidoglycans, in carcinogenesis, 629 Phenotypical antibiotic resistance, 521 Polymerase chain reaction, for antibiotic resistance, , Prebiotics, 566 Primary mismatch polymerase chain reaction, for antibiotic resistance, 584 Probiotics, 530, as adjuvant therapy, clinical use of, 567 curative use of, current use of, description of, Proliferative-type tumors, 627 Proton pump inhibitors. See also Bismuth quadruple therapy. diagnostic test reliability and, dosage of, , 556 gastric atrophy induced by, Pylera, 522, 527, Q Quadruple therapy bismuth, , nonbismuth, R Rabeprazole, 671 Radiotherapy, for MALT lymphoma, 657 Rapid urease test, Reactive nitrogen species, in gastric cancer, Reactive oxygen species, in gastric cancer, Rescue therapy,

7 697 Resistance, to antibiotics, See also specific antibiotics. fluoroquinolones, in bismuth quadruple therapy, macrolides, molecular determination of, nitroimidazoles, 591 rifampin, 590 tetracycline, Restriction length polymerization, for antibiotic resistance, , 590 Rifabutin, in triple therapy, Rifampin, resistance to, 590 S Saccharomyces boulardii formulations, 530, 569 Sampling, for biopsy, Scorpion format, for antibiotic resistance, 581 Sequencing, for antibiotic resistance, Sequential therapy, , 552 Serology tests, Single nucleotide polymorphism genotyping, for antibiotic resistance, Spasmolytic-polypeptide expressing metaplasia, 626 Spermine oxidase, in gastric cancer, Stool antigen tests, 512 Streptococcus faecium, Strip hybridization, 581, 588 Sydney classification system, for biopsy, Sydney System, for gastritis, 615 T TaqMan format, 581 Tetracycline, 522. See also Bismuth quadruple therapy. efficacy of, 524 resistance to, TNFAIP3 gene, in MALT lymphoma, 650 Triple therapy, efficacy of, Tumor necrosis factor, in gastric cancer, U Urea breath test, 512 Urease antigen, for vaccine development, V Vaccine, for Helicobacter pylori, animal models of, challenges in, clinical trials of, need for,

8 698 Vaccine (continued ) retrospective analysis of, Vacuolating cytotoxin A antigens of, for vaccine development, in carcinogenesis, 629 Virulence factors, in gastric cancer, W Western blot analysis, World Health Organization, gastric cancer classification of, 626 Wotherspoon score, for MALT lymphomas, 651